Inhibikase Therapeutics — Third Quarter 2026 Earnings Summary

Inhibikase Therapeutics reported a net loss of $20.5 million for the third quarter of 2026, driven by increased research and development expenses of $15.0 million. The company's cash position stood at $193.3 million as of September 30, 2026, following a $50 million equity financing completed in July. Regulatory approvals for the Phase 3 IMPROVE-PAH study have been secured in 28 countries, with 79 of 180 planned clinical sites currently activated. Additionally, the company announced the appointment of Dr. Scott M. Wasserman to its Board of Directors and received Orphan Drug Designation for its lead candidate, IKT-001.